News

Hamburg, March 5, 2024

• DTx priovi confirms effectiveness (RCT with 580 participants) in people with borderline personality disorder
...

Hamburg, 19. Januar 2024

Mit „Lamont“ startet ab sofort eine randomisierte kontrollierte Studie (RCT), die sich an Patient:innen mit Multipler Sklerose (MS) richtet. Die...

Hamburg, Dezember 2023

Unter dem Motto „Ökologische Psychiatrie und Psychotherapie” warf der diesjährige DGPPN Kongress ein Schlaglicht auf die aktuellen und zukünftigen klimawandelbedingten...

Hamburg, Mittwoch 27. September 2023

• Eine neue Depressionstherapie für MS-Patienten hat sich in einer großen klinischen Studie als wirksam erwiesen. Dies gab der Hersteller...

Hamburg/ Frankfurt, Mittwoch 10. Mai 2023 10.00 CEST

• Mehrjährige Partnerschaft für die Vermarktung im Bereich rheumatoide Arthritis (RA)
...

Hamburg, Montag 24. April 2023 14.00 CEST

Ab sofort stellt die HanseMerkur ihren Krankenvollversicherten, die unter Angststörungen oder Multipler Sklerose (MS) mit Erschöpfungs- und Ermüdungszuständen (Fatigue) leiden,...

Hamburg, Dienstag 07. März 2023 9.00 CEST

• Mit priovi steht ab sofort eine digitale Therapie zur Verfügung, die eine Lücke in der Versorgung von Borderline-Patient:innen schließt
...

Hamburg, Montag 06. März 2023 11.00 CEST

• GAIA ist seit diesem Jahr Mitglied im Verband der forschenden Pharma-Unternehmen (vfa)
...

Hamburg, Dienstag 10. Januar 2023 15.00 CEST

• Neue digitale Gesundheitsanwendung (DiGA) unterstützt MS-Patient:innen langfristig dabei, mit MS ein aktives und selbstbestimmtes Leben zu führen
...

Hamburg, Mittwoch 14. Juli 2022 12.30 CEST

Im Rahmen ihrer Brustkrebsbehandlung befinden sich die Patientinnen in einer emotionalen Achterbahnfahrt: Neben dem Gefühl, endlich ein neues, gesundes Leben...

Uppsala, Sweden and Hamburg, Germany, Wednesday 13. July 2022 15.30 CEST

Orexo, GAIA’s partner for the commercialization of deprexis®, GAIA’s evidence-based digital therapy for the treatment of symptoms of depression, announced...

Stockholm, Sweden, Tuesday 03. May 2022 11.29 CEST

In this trial, GAIA combined its digital therapeutic software platform with smart sensors, including a sensorized shirt that collects biomedical...

Hamburg, Germany, Donnerstag 14 April 2022 15.00 CEST

elevida, die aus dem Hause GAIA stammende Digitale Gesundheitsanwendung gegen Fatigue bei MS ist die bisher einzige Digitale Gesundheitsanwendung für...

Hamburg, Germany, Freitag 01 April 2022 17.00 CEST

Hamburg, 01.04.2022 - Als erste Digitale Gesundheitsanwendung (DiGA) bei Angst- und Panikstörungen wurde velibra bereits im Oktober 2020 in das...

Hamburg, Germany, Monday 15 November 2021 10.00 CEST

GAIA CEO, Dr. Mario Weiss sits down with ZS.com’s Lukas Grabner for a one-on-one interview about the successful development and...

Hamburg, Germany, Tuesday 02 November 2021 10.00 CEST

In a collaboration with Deloitte, GAIA released an extensive publication on the evolution and future of Digital Therapeutics.

Bern, Switzerland, Wednesday 15 Sep 2021 10.00 CEST

GAIA’s long-time research and development partner Prof. Dr. Thomas Berger is the 2021 recipient of the coveted “Swiss Nobel Prize”...

Hamburg, Germany, Montag 31 Mai 2021 10.00 CEST

GAIA AG today announced the appointment of Andreas Bertram as Chief Operating Officer. Andreas brings with him more than 25...

Hamburg, Germany, Montag 10 Mai 2021 10.00 CEST

Die von GAIA entwickelte digitale Gesundheitsanwendung (DiGA) vorvida®, ist letzte Woche in das DiGA-Verzeichnis des Bundesinstituts für Arzneimittel und Medizinprodukte...

Hamburg, Germany, Monday 03 May 2021 10.00 CEST

Stan Sugarman to join the Leadership Team and invest in GAIA AG.

Hamburg, Germany, Monday 04 January 2021 10.00 CEST

GAIA’s research project „Nevermind“ is published in the official „Success Story Yearbook 2020“ as one of nine EU funded projects...

Amsterdam, Netherlands, Wednesday 23 September 2020 10.00 CEST

According to a newly published observational study, GAIA’s digital therapeutic deprexis is effective in real-world routine medical care. These findings...

Bielefeld, Germany, Tuesday 23 June 2020 10.00 CEST

In the largest ever health economic evaluation of a digital therapeutic, researchers at the University Bielefeld found that GAIA’s deprexis...

Oxford, UK, Thursday 06 June 2020 10.00 CEST

The largest study to date on combining routine psychotherapy with digital therapeutics confirmed that adding GAIA’s deprexis significantly boosts treatment...

Hamburg, Germany, Thursday 06 February 2020 10.00 CEST

GAIA AG, one of the first developers of digital therapeutics worldwide, announces its successful certification by TÜV Rheinland, an independent...

Cambridge, UK, Thursday 30 January 2020 10.00 CEST

GAIA’s digital therapy reliably reduces depression symptoms over 8 to 12 weeks, according to a newly published meta-analysis. The researchers...

Hamburg, Tuesday 03 December 2019 12.00 CEST

The DAK-Gesundheit, one of Germany’s top insurance providers, released a report last week on the topic of depression among teens...

Toronto, Monday 04 November 2019 12.00 CEST

A randomized controlled trial (RCT) showed that adding GAIA’s digital therapy software, deprexis, to standard inpatient hospital treatment improved remission...

Hamburg, Friday 27 September 2019 12.00 CEST

September is #PainAwarenessMonth, a topic we’re glad to see being supported in social media. Chronic pain and the management of...

Bielefeld, Tuesday 04 June 2019 17.00 CEST

A newly published study once again confirmed the cost-saving effects of GAIA’s digital therapies. Specifically, health economic data were analyzed...

Hamburg, Tuesday 02 April 2019 17.00 CEST

GAIA’s fully automated digital therapeutic, vorvida, reduces risky drinking patterns in adults with alcohol addiction, according to a new randomized...

Hamburg, Friday 22 March 2019 16.00 CEST

GAIA’s Prostana® Reports Positive Signs from Both Urologists and Patients in an Interim Analysis

Hamburg, Monday 04 February 2019 16.00 CEST

A recently published RCT demonstrates GAIA AG has once again created a clinically effective digital therapy intervention, this time with...

Castrop-Rauxel, Thursday 17 January 2019 13.00 CEST

A new randomized controlled trial has confirmed that adding GAIA’s depression software deprexis significantly boosts treatment effectiveness. Inpatients at a...

Hamburg, Monday 10 December 2018 13.00 CEST

Over the past decade, GAIA’s research and development has focused on digital treatments based on artificial intelligence (AI) to improve...

Hamburg, Tuesday 18 September 2018 11.00 CEST

A high number of inpatient cases, hospitalization days and physician visits bloat healthcare spending without necessarily improving the quality of...

Hamburg, Wednesday 25 July 2018 11.30 CEST

A randomized controlled trial (RCT) of Emyna with 200 people living with epilepsy has shown very encouraging results.

Hamburg, Wednesday 13 June 2018 13.00 CEST

Significant reduction in gambling-related symptoms have been recorded following treatment with GAIA’s therapeutic software. Researchers from the University Medical Center...

Berlin, Monday 04 June 2018 12.00 CEST

Behavioral change is crucial for treating back pain. This message lies at the heart of our CEO’s presentation this Wednesday,...

Hamburg, Friday 18 May 2018 18.00 CEST

Can GAIA’s evidence-based therapy software improve the effectiveness of routine behavioral therapy? Yes! And a randomized controlled trial (RCT) has...

Rio de Janeiro, Friday 13 April 2018 11.00 BRT

Deprexis has launched in Brazil! Deprexis is a fully-automated therapy for individuals suffering from depressive disorders.

Hamburg, Tuesday 27 March 2018 09.00 GMT

GAIA’s fully automated therapy software, Elevida, reduces Multiple Sclerosis (MS) related fatigue in patients, a randomized controlled trial (RCT) has...

Berlin, Thursday 15 March 2018 11.45 GMT

Our partnership with DAK Gesundheit, a leading German health insurer, has been extended with the launch of Rücken@Fit. Continue reading

Hamburg, Thursday 22 February 2018 09.15 CET

A recent meta-analysis reveals that beyond clever marketing, several guided internet-based interventions fail to deliver cost effectiveness. Thus, it...

Dubai, Tuesday 30 January 2018 17.35 CET

The United Arab Emirates (UAE) will now use deprexis MS, GAIA’s digital therapy software, to treat depression in multiple sclerosis...

Munich, Monday 15 January 2018 06.35 CET

A randomized controlled trial (RCT) has provided powerful evidence that adding our digital software significantly improves inpatient treatment efficacy. This...

San Francisco, Tuesday 02 January 2018 10.00 PST

GAIA AG will present at the 2018 Biotech Showcase ™ to be held January 8 – 10 at the Hilton...

Berlin, Friday 15 December 2017 09.05 GMT

Can digital therapeutic interventions empower multiple sclerosis (MS) patients to better cope with symptom flare-ups? Can digital therapy software help...

Glasgow, UK, Thursday 30 November 2017 07.25 GMT

A new study confirms that deprexis® reduces total health insurance costs. GAIA’s leading digital therapy software is proven to facilitate...

Hamburg, Thursday 29 November 2017 06.35 GMT

Leading German news programme, Tagesschau has showcased consumer testimony highlighting the immense help GAIA’s fully automated therapy software is for...

Hamburg, Wednesday 16 August 2017 10.22 CST

Digital therapy is radically reshaping the healthcare landscape for a number of key reasons: Well-developed digital therapeutics can be as...

Oxford, UK, Friday 28 July 2017 11.09 GMT

A meta-analysis of GAIA’s digital therapy for depression (deprexis) has been published in the latest issue of the peer-reviewed scientific...

Exeter, UK, Wednesday 19 July 2017 14:19 GMT

In a new article coming out in Behaviour Research and Therapy, a team of leading researchers reported that one of...

Berlin, Thursday 20 April 2017 11.43 CST

Two GAIA-chaired symposia have been accepted by the Scientific Programme Committee of the World Congress of Psychiatry, to be held...

Berlin, Tuesday 18 April 2017 15.45 CST

Optimizing physicians’ prescription behavior in ambulatory care settings can be a challenge – particularly if the physicians are working in...

Austin, Texas, Friday 24 February 2017 13.36 CST

A randomized controlled trial with N = 376 depressed adults, published in the latest issue of the Journal of Consulting...

Amsterdam, Wednesday 22 February 2017 17.45 GMT

A new meta-analysis of individual patient data, published in the latest issue of JAMA Psychiatry, confirmed the efficacy of deprexis...

Hamburg, Tuesday 14 February 2017 18.00 GMT

Servier, the independent international pharmaceutical company, and GAIA, a global pioneer in digital therapy, have signed a partnership to extend...

Berlin, Friday 27 January 2017 17.00 GMT

A randomized controlled trial examined whether experienced psychotherapists can use one of GAIA’s interventions (Deprexis) to augment or enhance their...

San Francisco, Thursday 5 January 2017 15.00 GMT

We are pleased to announce that Gaia AG will present at the Digital Medicine Showcase 2017, as part of...

Hamburg, Wednesday 4 January 2017 10.00 GMT

GAIA has contributed a chapter on internet-based interventions for work-related mental disorders, which was recently published in the book “Arbeitsplatzbezogene...

Austin, Texas, Monday 12 December 2016 18.30 GMT

A randomized controlled trial with N = 376 adults with at least moderately severe depression has confirmed that Deprexis is...

Hamburg, Friday 9 December 2016 14.30 GMT

A randomized controlled trial testing the efficacy of vorvida, our intervention for adults trying to reduce excessive alcohol consumption, has...

Hamburg, Tuesday 6 December 2016 9.00 GMT

Mario Weiss (CEO GAIA) and Michael Nick ( EVP Business Development) will attend the 35th annual JP Morgan Healthcare Conference...

Hamburg, Friday 2 December 2016 11.15 GMT

Elevida, our cognitive-behavioural therapy software for patients with multiple sclerosis has been demonstrated to be effective in a randomized controlled...

Zurich, Thursday 10 November 2016 16.00 GMT

The Sanitas health insurance, covering almost 10% of the Swiss population, has been awarded the Innovation Award 2016 of the...

Bern, Monday 12 September 2016 10.00 GMT

After nearly four years of research and development, we are proud to announce that velibra, our digital therapy software for...

Hamburg, Monday 15 August 2016 11.30 GMT

The French pharma company and GAIA entered into a marketing and sales cooperation for deprexis in Germany. Servier will promote...

Hamburg, Saturday 30 April 2016 12.30 GMT

Veovita and the DAK-G statutory health insurance today reached an agreement that will help thousands of people getting faster and...

Hamburg, Thursday 21 January 2016 10.30 GMT

Deprexis in Italian and Portuguese: Deprexis is now available in Italian and Portuguese/Brazilian. These newly translated were developed by GAIA...

Zurich, Saturday 12 December 2015 09.30 GMT

GAIA and the Swiss statutory health insurance today signed a comprehensive cooperation agreement that will help Sanitas to leverage the...